ArticleThe journal of headache and pain2024
Identifying therapeutic target genes for migraine by systematic druggable genome-wide Mendelian randomization.
Article in The journal of headache and pain, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Exploring the association between statins use or HMG-CoA reductase inhibition and migraine: a systematic review and meta-analysis.The journal of headache and pain · 2025Pooled it
- Causal factors for migraine in Mendelian randomization studies: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Identifying therapeutic target genes for rheumatoid arthritis-associated interstitial lung disease by systematic druggable genome-wide Mendelian randomization analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The Genetic and Transcriptomic Nexus of Age-Related Hearing Loss and Alzheimer's Disease.Genes · 2026Article
- Systematic druggable genome-wide mendelian randomization identifies therapeutic targets for childhood asthma.Medicine · 2025Article
- DNA methylation and bronchiectasis: a Mendelian randomization analysis to investigate causal link and therapeutic target.Epigenetics · 2025Article
- A single-cell multi-omics framework identifies immune cell drivers of migraine and repurposable therapeutics.The journal of headache and pain · 2025Article
- Dissecting immune cell-specific genetics in migraine: a multi-omics framework for target discovery and therapeutic prioritization.The journal of headache and pain · 2025Article
- Precision Target Discovery for Migraine: An Integrated GWAS-eQTL-PheWAS Pipeline.Molecules (Basel, Switzerland) · 2025Article
- Systematic Exploration of Potential Druggable Genes for Ischemic Stroke Employing Genome-Wide Mendelian Randomization Analysis.Brain and behavior · 2025Article
- Identification of potential drug targets for achalasia from genetic insights: a Mendelian randomization study.Journal of cardiothoracic surgery · 2025Article
- Andrographolide Mitigates Inflammation and Reverses UVB-Induced Metabolic Reprogramming in HaCaT Cells.International journal of molecular sciences · 2025Article
- The lactylation-immune regulatory axis: a potential therapeutic target for migraine prevention and treatment.The journal of headache and pain · 2025Article
- Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for osteoporosis.Osteoporosis and sarcopenia · 2025Article
- Metabolic Dysfunction and Dietary Interventions in Migraine Management: The Role of Insulin Resistance and Neuroinflammation-A Narrative and Scoping Review.Brain sciences · 2025Review
- Identifying therapeutic target genes for diabetic retinopathy using systematic druggable genome-wide Mendelian randomization.Diabetology & metabolic syndrome · 2025Article
- Identification of Therapeutic Targets for Hyperuricemia: Systematic Genome-Wide Mendelian Randomization and Colocalization Analysis.Biomedicines · 2025Article
- Identification of galangin as a therapeutic candidate for primary biliary cholangitis via systematic druggable genome-wide Mendelian randomization analysis and experimental validation.Frontiers in pharmacology · 2025Article
- A multi-stage genomic approach to uncover druggable gene targets and neural pathways in postpartum depression.Archives of medical science : AMS · 2025Article
- The role of digital device use on the risk of migraine: a univariable and multivariable Mendelian randomization study.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, the treatment and prevention of migraine remain highly challenging. Mendelian randomization (MR) has been widely used to explore novel therapeutic targets. Therefore, we performed a systematic druggable genome-wide MR to explore the potential therapeutic targets for migraine.
methodsWe obtained data on druggable genes and screened for genes within brain expression quantitative trait locis (eQTLs) and blood eQTLs, which were then subjected to two-sample MR analysis and colocalization analysis with migraine genome-wide association studies data to identify genes highly associated with migraine. In addition, phenome-wide research, enrichment analysis, protein network construction, drug prediction, and molecular docking were performed to provide valuable guidance for the development of more effective and targeted therapeutic drugs.
resultsWe identified 21 druggable genes significantly associated with migraine (BRPF3, CBFB, CDK4, CHD4, DDIT4, EP300, EPHA5, FGFRL1, FXN, HMGCR, HVCN1, KCNK5, MRGPRE, NLGN2, NR1D1, PLXNB1, TGFB1, TGFB3, THRA, TLN1 and TP53), two of which were significant in both blood and brain (HMGCR and TGFB3). The results of phenome-wide research showed that HMGCR was highly correlated with low-density lipoprotein, and TGFB3 was primarily associated with insulin-like growth factor 1 levels.
conclusionsThis study utilized MR and colocalization analysis to identify 21 potential drug targets for migraine, two of which were significant in both blood and brain. These findings provide promising leads for more effective migraine treatments, potentially reducing drug development costs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.